Cargando…

EP1278: EFFICACY OF TOTAL ENTERAL NUTRITION COMBINED WITH AZATHIOPRINE IN MAINTAINING POSTOPERATIVE REMISSION IN CROHN'S DISEASE: A PARALLEL, RANDOMIZED CONTROLLED STUDY

Detalles Bibliográficos
Autores principales:	Duan, Ming, Cao, Lei, Zhu, Weiming, Li, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AGA Institute. Published by Elsevier Inc. 2022
Materias:	AGA Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212634/ http://dx.doi.org/10.1016/S0016-5085(22)62601-5

Ejemplares similares

EP1272: DIETARY LIPIDS FUEL METABOLIC ENTERITIS IN CROHN'S DISEASE
por: Schwärzler, Julian, et al.
Publicado: (2022)

EP1277: EFFICACY OF CARBON DIOXIDE INSUFFLATION DURING COLONOSCOPY FOR PATIENTS WITH ULCERATIVE COLITIS IN CLINICAL REMISSION -A RANDOMIZED TRIAL-
por: Otake, Yuriko, et al.
Publicado: (2022)

EP1276: USTEKINUMAB HAS COMPARABLE LONG-TERM EFFECTIVENESS AS ANTI-TNF AGENTS IN BIOLOGIC-NAÏVE PATIENTS WITH CROHN'S DISEASE
por: Shiga, Hisashi, et al.
Publicado: (2022)

Low-dose azathioprine is effective in maintaining remission among Chinese patients with Crohn’s disease
por: Wu, Jianghong, et al.
Publicado: (2013)

Su1501: PROPHYLACTIC VERSUS ENDOSCOPY DRIVEN TREATMENT OF CROHN'S POSTOPERATIVE RECURRENCE: A RETROSPECTIVE MULTICENTRIC EUROPEAN STUDY
por: Geldof, Jeroen, et al.
Publicado: (2022)

Low dose of azathioprine is effective to induce and maintain remission in active Crohn disease: A prospective observational study
por: Qian, Xiaoxian, et al.
Publicado: (2018)

EP1270: SEROCONVERSION IN INFLAMMATORY BOWEL DISEASE PATIENTS AFTER COVID-19 VACCINATION
por: Horvath, Miklos, et al.
Publicado: (2022)

EP1019: THE EFFECTS OF THE COVID-19 PANDEMIC ON PRESENTATIONS AND DIAGNOSIS OF UPPER GI AND HEPATOPANCREATICOBILIARY MALIGNANCIES
por: Carroll, Andrew, et al.
Publicado: (2022)

EP1018: GASTROINTESTINAL BLEEDING DURING THE COVID-19 PANDEMIC: IMPACT ON PATIENT PRESENTATION AND OUTCOMES
por: Kerbage, Anthony, et al.
Publicado: (2022)

EP1020: THE PREVALENCE OF GASTROINTESTINAL SYMPTOMS IN ACUTE COVID-19 INFECTION EVALUATED WITH A DIGITAL QUESTIONNAIRE
por: Malderen, Kathleen Van, et al.
Publicado: (2022)

EP1017: CHANGING PERFORMANCE OF COLORECTAL CANCER SCREENING FOLLOWING A COVID-19 PANDEMIC IN KOREA
por: Kim, Hyun-Soo, et al.
Publicado: (2022)

Sa078 CLINICAL AND LABORATORY MARKERS DO NOT PREDICT DEEP HISTOLOGIC REMISSION IN PATIENTS WITH ULCERATIVE COLITIS
por: Sharma, Disha, et al.
Publicado: (2021)

EP1021: CHANGES IN THE NEEDS OF IBD PATIENTS FOR TREATMENT BEFORE AND AFTER THE COIVD19 EPIDEMIC (ANALYSIS USING TWITTER DATA)
por: Fuchigami, Ayako
Publicado: (2022)

EP1273: PRACTICAL APPLICATION OF EVIDENCE-BASED DIETARY THERAPY INTO INFLAMMATORY BOWEL DISEASE CARE. PATIENT SATISFACTION, COMPLIANCE, AND EFFICACY. THE DELECTABLE PROGRAM.
por: Russell, Erin, et al.
Publicado: (2022)

EP1269: INTERIM ANALYSIS OF A MULTICENTER REGISTRY STUDY OF COVID-19 INFECTED PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN JAPAN (J-COSMOS).
por: Hayashi, Yuki, et al.
Publicado: (2022)

Sa1273: ENTERIC NEURONAL VASOACTIVE INTESTINAL PEPTIDE MEDIATES SARS-COV-2 ASSOCIATED DIARRHEA
por: Balasubramaniam, Arun, et al.
Publicado: (2022)

Su094 IMMUNE AND METABOLIC PATHOGENESIS OF ENVIRONMENTAL ENTERIC DYSFUNCTION IN CHILDHOOD UNDERNUTRITION: A BIRTH INCEPTION COHORT
por: Haberman, Yael, et al.
Publicado: (2021)

1160: PERCUTANEOUS GASTROSTOMY PLACEMENT IN PATIENTS WITH COVID-19 INFECTION: CLINICAL OUTCOMES AND THE INFREQUENT NEED FOR LONG-TERM ENTERAL ACCESS
por: Levine, Irving, et al.
Publicado: (2022)

EP1271: UNPLANNED HOPSITAL ADMISSION AND EMERGENCY ATTENDANCE FOLLOWING TWO-DOSE OF BNT162B2 AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED COHORT STUDY
por: Li, Xue, et al.
Publicado: (2022)

Sa1051: UTILIZATION OF A MULTIDISCIPLINARY TELEHEALTH MODEL TO IMPROVE ACCESS TO CARE AND MAINTAIN AN ACADEMIC TEACHING PARADIGM FOR A UNIQUE PATIENT POPULATION DURING THE COVID-19 PANDEMIC
por: Reddy, Kavya, et al.
Publicado: (2022)

Prolonged Remission of Psoriasis with Azathioprine Pulse Therapy
por: Gupta, Ramji
Publicado: (2015)

Exclusive Enteral Nutrition Induces Remission in Pediatric Crohn's Disease via Modulation of the Gut Microbiota
por: Gong, Dawei, et al.
Publicado: (2017)

Maintenance of Remission with Partial Enteral Nutrition Therapy in Pediatric Crohn's Disease: A Retrospective Study
por: Schulman, Jacqueline M., et al.
Publicado: (2017)

Discontinuation of Azathioprine could be considered in pediatric patients with Crohn’s disease who have sustained clinical and deep remission
por: Jeong, Tae Jong, et al.
Publicado: (2022)

Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

Exclusive enteral nutrition with concomitant early thiopurine use was effective in maintaining steroid-free remission in a Southeast Asian cohort of children with Crohn’s disease
por: Ong, Christina, et al.
Publicado: (2018)

Thalidomide Combined With Azathioprine as Induction and Maintenance Therapy for Azathioprine-Refractory Crohn's Disease Patients
por: Li, Tong, et al.
Publicado: (2020)

Lactobacillus GG in inducing and maintaining remission of Crohn's disease
por: Schultz, Michael, et al.
Publicado: (2004)

Exclusive enteral nutrition mediates gut microbial and metabolic changes that are associated with remission in children with Crohn’s disease
por: Diederen, Kay, et al.
Publicado: (2020)

Bacterial Taxa and Functions Are Predictive of Sustained Remission Following Exclusive Enteral Nutrition in Pediatric Crohn’s Disease
por: Jones, Casey M A, et al.
Publicado: (2020)

Outcomes of Pediatric Patients with Crohn's Disease Received Infliximab or Exclusive Enteral Nutrition during Induction Remission
por: Lv, Yao, et al.
Publicado: (2022)

The Role of Partial Enteral Nutrition for Induction of Remission in Crohn’s Disease: A Systematic Review of Controlled Trials
por: González-Torres, Lucía, et al.
Publicado: (2022)

Combined evaluation of biomarkers as predictor of maintained remission in Crohn’s disease
por: Sollelis, Elisa, et al.
Publicado: (2019)

Lymphomatoid granulomatosis associated with azathioprine therapy in Crohn disease
por: Connors, William, et al.
Publicado: (2014)

Redox imbalance in Crohn's disease patients is modulated by Azathioprine
por: Tavassolifar, Mohammad Javad, et al.
Publicado: (2021)

Synergistic effect of enteral nutrition on remission induction in a patient with penetrating Crohn disease: A case report
por: Xie, Chenxi, et al.
Publicado: (2019)

Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn’s disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course
por: Harris, Rachel E, et al.
Publicado: (2020)

Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn’s disease: the Indian experience
por: Sood, Ajit, et al.
Publicado: (2020)

Recalcitrant plantar warts during azathioprine therapy for Crohn’s disease
por: Timmer, Margriet R., et al.
Publicado: (2013)

Resected Hepatocellular Carcinoma in a Patient with Crohn's Disease on Azathioprine
por: Heron, Valérie, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2lcao6q0i8kbeenma5lciv1d9j